$71.00
HMG contains both FSH and LH activity — the two pituitary hormones that drive follicle development and ovulation. Used in assisted reproduction protocols, it is one of the most clinically established fertility compounds available.
3-5 business days
SSL encrypted
Human menopausal gonadotropin (HMG) is derived from the urine of postmenopausal women and contains both FSH (follicle-stimulating hormone) and LH (luteinizing hormone) in a 1:1 ratio. FSH stimulates ovarian follicle development and estrogen production; LH triggers ovulation and supports the corpus luteum. Together, they represent the core pituitary signal that drives the menstrual cycle’s follicular and ovulatory phases.
HMG is used clinically in controlled ovarian stimulation (COS) protocols for IVF and IUI, as well as for ovulation induction in women with anovulatory cycles. Its combined FSH/LH activity makes it more physiologically complete than recombinant FSH alone in cases where LH activity is needed — particularly in women who are hypogonadotropic or who have insufficient LH support for follicle maturation. Research protocols also explore its role in restoring ovarian function after suppression.
Female-calibrated dosing: 75–150 IU subcutaneously daily during the follicular phase (days 2–12 of cycle), under direct medical supervision with ultrasound monitoring and hormone tracking. This is a clinical fertility compound and should only be used as part of a supervised ART or ovulation induction protocol.
Storage: Store lyophilized powder at room temperature before reconstitution, below 25°C. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.
| Dosage | 75 IU |
|---|---|
| Format | Injectable Vial |
| Cycle Length | Cycle-phase dependent |
| Storage | Store below 25°C before reconstitution. Refrigerate after reconstitution. Use within 28 days. |
Reviews
There are no reviews yet.